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Evaluation of Microparticulate Ovarian Cancer Vaccine via Transdermal Route of 
Delivery 
Abstract 
Ovarian cancer is the fifth most commonly occurring malignancy in women, with the highest mortality 
rate among all the gynecological tumors. Microparticulate vaccine can serve as an immunotherapeutic 
approach with a promising antigenic delivery system without a need for conventional adjuvants. In this 
study, a microparticulate vaccine using whole cell lysate of a murine ovarian cancer cell line, ID8 was 
prepared by spray drying. Further, the effect of interleukins (ILs) such as IL-2 and IL-12 was evaluated in a 
separate study group by administering them with vaccine particles to enhance the immune response. The 
vaccine microparticles were administered to C57BL/6 female mice via transdermal alone and in 
combination with the oral route. The transdermal vaccine was delivered using a metallic microneedle 
device, AdminPen™. Orally administered microparticles also included an M-cell targeting ligand, Aleuria 
aurantia lectin, to enhance the targeted uptake from microfold cells (M-cells) in Peyer's patches of small 
intestine. In case of combination of routes, mice were given 5 transdermal doses and 5 oral doses 
administered alternatively, beginning with transdermal dose. At the end of vaccination, mice were 
challenged with live tumor cells. Vaccine alone resulted in around 1.5 times tumor suppression in case of 
transdermal and combination of routes at the end of 15th week when compared to controls. Inclusion of 
interleukins resulted in 3 times tumor suppression when administered with transdermal vaccine and 
around 9 times tumor suppression for the combination route of delivery in comparison to controls. These 
results were further potentiated by serum IgG, IgG1 and IgG2a titers. Moreover, CD8+ T-cell, CD4+ T-cell 
and NK (natural killer) cell populations in splenocytes were elevated in case of vaccinated mice. Thus, 
vaccine microparticles could trigger humoral as well as cellular immune response when administered 
transdermally and via combination of route of delivery. However overall, vaccine administered with 
interleukins, via combination of route, was found to be the most efficacious to suppress the tumor growth 
and lead to a protective immune response. 
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Abstract: Ovarian cancer is the fifth most commonly occurring malignancy in women, with the 
highest mortality rate among all the gynecological tumors. Microparticulate vaccine can serve as 
an immunotherapeutic approach with a promising antigenic delivery system without a need for 
conventional adjuvants. In this study, a microparticulate vaccine using whole cell lysate of a 
murine ovarian cancer cell line, ID8 was prepared by spray drying. Further, the effect of 
interleukins (ILs) such as IL-2 and IL-12 was evaluated in a separate study group by administering 
them with vaccine particles to enhance the immune response. The vaccine microparticles were 
administered to C57BL/6 female mice via transdermal alone and in combination with the oral 
route. The transdermal vaccine was delivered using a metallic microneedle device, AdminPenTM. 
Orally administered microparticles also included an M-cell targeting ligand, Aleuria aurantia 
lectin, to enhance the targeted uptake from microfold cells (M-cells) in Peyer's patches of small 
intestine. In case of combination of routes, mice were given 5 transdermal doses and 5 oral doses 
administered alternatively, beginning with transdermal dose. At the end of vaccination, mice were 
challenged with live tumor cells. Vaccine alone resulted in around 1.5 times tumor suppression in 
case of transdermal and combination of routes at the end of 15th week when compared to controls. 
Inclusion of interleukins resulted in 3 times tumor suppression when administered with 
transdermal vaccine and around 9 times tumor suppression for the combination route of delivery 
in comparison to controls. These results were further potentiated by serum IgG, IgG1 and IgG2a 
titers. Moreover, CD8+ T-cell, CD4+ T-cell and NK (natural killer) cell populations in splenocytes 
were elevated in case of vaccinated mice. Thus, vaccine microparticles could trigger humoral as 
well as cellular immune response when administered transdermally and via combination of route 
of delivery. However overall, vaccine administered with interleukins, via combination of route, 
was found to be the most efficacious to suppress the tumor growth and lead to a protective immune 
response.  
1. Introduction: 
Ovarian cancer is the most lethal gynecological cancer and the fifth most leading cause of cancer 
related deaths in women in the US [1, 2]. The National Cancer Institute (NCI) has estimated 
21,290 new cases and 14,180 deaths due to ovarian cancer in the US in 2015.  When 
cancer incidences are compared worldwide, the mortality rate associated with ovarian cancer was 
found to be relatively high in the US and Europe [3]. Since it is very difficult to detect an ovarian 
cancer, especially in the early stages, it is referred to as a ‘silent killer’. Only about 10% of 
ovarian cancers are usually found in the early stages. Patients with epithelial tumors, which 
account for approximately 90% of ovarian cancer, generally have poor overall survival and the 
5-year survival for stages III–IV of these tumors is about 29.1% [4]. The first-line treatment for 
advanced ovarian cancer involves surgery to remove the tumor, followed by chemotherapy. 
However, the cancer relapses within relatively short periods of time even after treatment. It has 
been reported that up to 75% of patients responding well to the initial treatments face tumor 
relapse within 18–28 months [5]. Moreover, chemotherapeutic treatments for cancer are toxic 
and/or of minimal therapeutic value. Therefore, alternative approaches such as immunotherapy is 
being investigated to prevent relapse of cancer. Several vaccines are underway in clinical trials 
and most of them have not progressed beyond phase I/II studies [6, 7].  
 
Various proteins and peptides have been approved or are being evaluated in clinical trials for 
treatment of cancer. Due to limited oral bioavailability of such antigens, injectable routes of 
administration are currently being used. Scientists have been exploring the potential of delivering 
vaccine antigens orally or transdermally as these delivery routes have ease of administration, are 
non-invasive and patient compliant. Transdermal delivery is considered as the best route for 
vaccine administration because of the skin-associated lymphoid tissue which comprises of 
Langerhans cells, dermal dendritic cells, lymph nodes and subsets of T-lymphocytes. 
Microneedles have been used to pierce the upper layer- Stratum corneum of the skin to enhance 
transdermal delivery by promoting the transport of macromolecules that cannot be delivered 
across the skin by passive diffusion alone [8, 9]. Microneedles are micron-sized needles, which 
upon insertion into the skin result in formation of aqueous conduits forming a passage for the 
vaccine antigens towards the immune-competent skin layers. Due to their short needle length, 
they avoid contact with the nerve endings in the dermis thus remain to be a painless mode of 
immunization [10-12].  
 
In addition, the microparticulate delivery system has several advantages over the usage of the 
antigens alone. Particulate antigens have been proven to be more immunogenic than soluble 
antigens [13, 14]. Improved uptake of the particles compared to the solution results in higher 
cytotoxic T-lymphocytes (CTLs) response against the cancer cells. The antigen presenting cells 
(APCs) in the body easily phagocytose these microparticles recognizing them as an antigen and 
generate an immune response [15]. Further, they are drained into the nearby lymph nodes where 
they activate various other immune cells. Thus, the particulate delivery systems may mimic 
pathogens that are commonly recognized, phagocytosed and processed by professional antigen- 
presenting cells (APC) [16, 17]. When administered transdermally, the microparticles are taken 
up by the immune cells in the skin, which trigger mucosal as well as systemic immune response 
[10]. Langerhans cells are dendritic cells that activate T cells and induce a strong immune 
response and occupy around 20% of the skin’s area. On the other hand, M-cells are the microfold 
cells, which act as sampling ports for any foreign entities encountered in the small intestine upon 
oral administration [18-23]. These M cells house various dendritic cells and immune cells in 
them. Once the oral vaccine particle is sampled by M-cells, it is processed by a dendritic 
cell/antigen presenting cell (APC) and presented on MHC (major histocompatibility complex) 
Class I or MHC Class II molecules [24, 25]. The antigens are further recognized by the immune 
cells in the vicinity leading to the cascade of an immune response.  The immune response also 
includes humoral response by plasma B-cells, which leads to production of antibodies and their 
class switching. The role of B-cells has been debatable in past but a recent study by Mahmoud 
SM et al. shows that the humoral immunity is important in addition to cell-mediated immunity in 
prognosis of breast cancer [26]. Thus, we aim to trigger both humoral and cell-mediated immune 
response through this prophylactic cancer vaccine, which can impart resistance against tumor 
challenge. Moreover, the microparticulate drug delivery system can be used to assimilate various 
antigens in one delivery system that can reduce the number of doses as well as reduce the 
different vaccination regimen [13, 14].  
 
In this study, we have investigated whether vaccination with microparticles containing the 
ovarian cancer antigens can prevent/ retard ovarian cancer growth. A murine ovarian cancer cell 
line, ID8 was used as a source of antigens for vaccine preparation. The cell line correlates closely 
to human ovarian cancer cell lines in signaling pathways and results in development of tumor in 
mice models similar to human ovarian cancer. Thus, ID8 cell line provides a unique model to 
study the immune response developed by the vaccine against the initiation and progression of 
ovarian cancer in mice with an intact immune system [2]. Therefore, we proceeded with a whole 
cell lysate of ID8 cells to prepare the vaccine for this study.  Despite of advancement in 
recombinant technology and gene expression, the whole cell lysate vaccine still remains a very 
promising approach. Whole cell lysate provides a pool of tumor-associated antigens (TAAs) 
which can induce both CD8+ and CD4+ T cells [27].  
 
In our previous study, microparticulate vaccine was found to be efficacious when administered 
orally [23]. Therefore, we aimed to evaluate the microparticulate vaccine via transdermal route 
alone and in combination with oral route. By combination route of administration, aim was to 
achieve merits of both oral and transdermal immunization [28]. The vaccine particles were 
administered for this purpose using a microneedle device called as AdminPenTM.  For this 
purpose, microparticles were prepared by spray drying technique using methacrylic copolymer 
Eudragit® FS 30 D and hydroxyl propyl methyl cellulose acetate succinate (HPMCAS) as 
described elsewhere [20, 23].  These polymers have been reported their applications for 
transdermal delivery in form of patches as well as particulates [29, 30]. Several others have 
mentioned their usage for oral sustained or controlled release delivery [31, 32]. To target the 
vaccine formulation to M-cells in the Peyer’s patches of the intestine upon oral delivery, M-cell 
targeting agent, Aleuria aurantia lectin (AAL) was used in the formulation [15, 20, 21]. In 
addition, immunostimulatory molecules such as IL-2 and IL-12 were added in order to enhance 
the overall potency of the formulated vaccines. Oral delivery was performed by using an oral 
gavage. Transdermal delivery was achieved using an AdminPenTM device comprised of an array 
of 43 metallic microneedles of 1100 nm length in 1 cm sq area of circular microneedle array 
made of SS316 stainless steel (as shown in figure 1). In the present study, we demonstrate and 
compare the efficacy of the vaccine formulation which was administered via two different 
approaches based on route of administration: (1) transdermal and (2) combination of transdermal 
and oral route in vivo in mouse tumor model.  
 
 
 
 
Fig. 1: AdminPenTM device comprised of an array of 43 metallic microneedles of 1100 nm length 
in 1 cm sq area of circular microneedle array made of SS316 stainless steel, attached to a syringe 
(Image produced with a permission from AdminMed / nanoBioSciences LLC) 
 
2. Materials and Methods 
2.1. Materials 
ID8 cell line was kindly provided by Dr. Katherine Roby, Kansas University Medical Center, 
Kansas City, KS. Six to eight week-old C57BL/6 female mice were purchased from Charles 
River Laboratories, Wilmington, MA. HPMCAS was purchased from AQOAT, FMC 
Biopolymers, Philadelphia, PA. Eudragit® FS 30 D was generously gifted by Evonik industries, 
Parsippany, NJ. Mouse plasma was obtained from Biochemed, Winchester, VA. AAL was 
obtained from Vector Labs, Inc., Burlingame, CA. Recombinant murine interleukins, IL-2 (5 X 
106 units/mg) and IL-12 (1 X 107 units/mg) were purchased from Peprotech Inc., Rocky Hill, NJ. 
Flow cytometry cell markers were purchased from eBioscience, San Diego, CA. Goat anti-
mouse HRP-IgG and anti-IgG subtypes were purchased from Bethyl Laboratories, Montgomery, 
TX and Sigma, St. Louis, MO respectively. AdminPenTM device was purchased from 
nanoBioSciences LLC. All other materials used were of analytical grade.  
 
2.2. Preparation and characterization of whole cell lysate of ID8 ovarian cancer cell line 
The whole cell lysate of the murine ovarian cancer ID8 cells was prepared using hypotonic 
buffer and freeze-thaw cycles as described elsewhere [23, 33, 34]. The lysate obtained was 
stored at -80⁰ C until used.   The whole cell lysate of ID8 cell line was characterized for total 
protein content using Bio-Rad DCTM protein assay. The lysate was also screened for presence of 
the only known marker, by western blot analysis as described elsewhere [23, 35].  
 
2.3. Preparation and characterization of vaccine microparticles  
The vaccine formulation was prepared by using spray drying technique as described elsewhere 
[20]. Briefly, hydroxyl propyl methyl cellulose acetate succinate (HPMCAS) and Eudragit® FS 
30D were dissolved in an alkaline solution, followed by addition of chitosan glycol. Mouse 
plasma, trehalose, and tween 20 were added to the solution. Whole cell lysate obtained from ID8 
cells (5%w/w) was added to this feed mixture and temperature was maintained at 4⁰ ± 2⁰ C 
throughout the spraying. This aqueous solution was spray dried using Buchi B-191 Mini Spray 
Dryer (Buchi Corporation, New Castle, DE) at inlet temperature 125° C, outlet temperature 80° 
C, 500Nl/h, and 2% spray flow feed rate (10 mL per 30 min) of peristaltic pump, and nozzle 
diameter 0.7 mm . The particles were characterized for size and charge, using laser particle 
counter (Spectrex PC -2000) (n=3) and Malvern zeta sizer (ZEN 1600) (n=10) respectively. 
Loading efficiency was determined by Biorad DCTM protein assay by extracting the lysate in 
phosphate buffered saline. 
 
2.4. Immunization 
The immunogenicity of microparticulate vaccine was evaluated using C57BL/6 female mice 
model. The animal experiments were carried out as per approved protocols by Mercer 
University’s Institutional Animal Care and Use Committee (IACUC). Animals (n=8) were 
administered with microparticles as one prime dose followed by one booster after one week and 
thereafter by 8 boosters with an interval of two weeks. In case of vaccine with interleukins 
formulations, 4 x 105 U of IL-2 and 8 x 105 U of IL-12 were added to this particulate suspension. 
For delivering microparticles via transdermal route, mice skin was shaved two days prior to 
vaccination.  Around 5 mg of microparticles were suspended in citrate buffer, pH 4.0 containing 
PEG 8000 as a viscosity modifier [11]. These mice were vaccinated by delivering this 
microparticulate suspension through AdminPenTM 1200 microneedle liquid injection system 
(refer to figure 1) which allows particles to seep into microchannels created by microneedles. For 
oral route, 5 mg of microparticles was suspended in citrate buffer and administered orally using 
oral gavage. In case of combination of routes, mice were given 5 transdermal doses and 5 oral 
doses administered alternatively, beginning with transdermal dose. In a study by Chiriva-
Internati et al., SP17 protein has been evaluated as an ovarian cancer vaccine in murine models, 
where the mice were immunized intramuscularly with SP17 in ten doses of vaccination. It has 
shown to be a promising approach prophylactically as well as therapeutically [35]. The number 
of doses were decided based on the previous successful particulate vaccine studies conducted by 
the group [23]. The booster doses were intended to potentiate the immune response by repeated 
exposure of the antigen every alternate week. Three different formulations such as placebo, 
vaccine and vaccine with interleukins were evaluated for this purpose.  
 
2.5. Tumor challenge study 
One week after the last vaccination, the mice were challenged s.c. with 1x107 live ID8 cells as 
described elsewhere [36, 37]. The cells were injected into the right back flank of mice. Tumor 
development was monitored using digital Vernier calipers. The mice were euthanized whenever 
the tumor ulcerated or tumors exceeded a size of 15 mm in any of the perpendicular diameters. 
The tumor volume (V) was determined by using the formula, V=1/2(Length) (Width)2 [36, 38]. 
 
2.6.  Assessment of humoral (B-cell mediated) immune response in serum 
The blood samples were collected prior to each dose of vaccination. Serum was analyzed by 
ELISA as described elsewhere. Briefly, a 96 well plate coated with the lysate (100µg/well) was 
incubated with 1: 10 dilution of serum samples. HRP-tagged secondary anti-mouse goat IgG was 
then added to each well, and incubated for 1 hr. TMB substrate reagent (3,3’, 5,5”-tetramethyl 
benzidine) (BD OptEIATM, BD Biosciences, CA) was added and the plate was again incubated 
for 30 min. The reaction was stopped by addition of 4N H2SO4.  The plate was read using 
microplate reader (BioTek instruments Inc., Winooski, VT) at 450 nm. In case of IgG subtypes 
analysis, serum samples were analyzed in dilution of 1:400. The plate was then incubated with 
goat anti-mouse IgG subtype IgG1 or IgG2a, followed incubation with HRP-conjugated anti-goat 
IgG. Thereafter, same procedure as described above for IgG titers analysis was followed.  
 
2.7. Determination of T-cell based/ cellular immune response  
A separate group of mice was vaccinated in similar way as described in section 2.4. At the end of 
vaccination, mice were euthanized and the spleens were harvested. The single cell suspension of 
pooled splenocytes were stimulated for 5 days at 37⁰C with mitomycin-treated tumor cells in a 
ratio 10:1 with 10 U/mL of recombinant murine IL-2. At the end of 5-days, the cells were 
washed with Hank’s balanced salt solution and labeled with anti-mouse CD8a FITC (for CD8+ 
T-cells), anti-mouse CD4 PE (for CD4+ T-cells), and anti-mouse NK PE (for NK cells). The 
cells were analyzed for the specific cell populations by flow cytometric analysis using BD 
accuri® C6 flow cytometer [23].  
 
2.8. Statistical analysis 
Serum IgG subtype titers and flow-cytometry results were analyzed using one-way analysis of 
variance (ANOVA) followed by Tukey’s multiple comparison test. Tumor volume 
measurements and serum IgGs were analyzed by two-way ANOVA followed by Bonferroni 
multiple comparisons. All statistical analyses were performed using GraphPad Prism5 (trial 
version 5.04, GraphPad Software, Inc., La Jolla, CA). For each test, p value less than 0.05 was 
considered significant. Data are expressed as mean ± standard error. 
 
3. Results and Discussion 
3.1. Preparation and characterization of the whole cell lysate 
The total protein concentration of lysate was 1.56 ± 0.5 mg/mL. The western blot analysis of the 
lysate showed the presence of SP17 antigen in the lysate prepared (shown elsewhere) [23]. The 
only protein which is expressed by ID8 cells and that has been studied is the sperm protein 
(SP17, molecular weight 15kD). It is one of the cancer/testis antigens, a sub- class of TAAs. It is 
non-mutated self-antigen which is reported to be recognized by CD8+ T-cells. This protein has 
been found to be expressed or over-expressed in ovarian cancers. Moreover, human SP17 shows 
70% homology with murine SP17. Thus, SP17 is a promising antigen for immunotherapy in 
ovarian cancer [35]. Therefore, the presence of SP17 in the lysate ensured that the protein 
cocktail obtained was antigenic when given as a vaccine.  
 
3.2. Preparation and characterization of vaccine microparticles  
The particles obtained were of 1.58 ± 0.62 µm size with a charge of 12.48 ± 2.32 mV. There was 
no significant change in size and charge upon loading these particles with the lysate. The 
production yield was 72.58 ± 3.41 % w/w. The loading efficiency of the particles was 92.68 ± 
4.77% w/w. These microparticles were within the size range to mimic pathogenic species; 
thereby enhancing the potential of naturally being phaygocytosed by dendritic cells. Thus, the 
uptake would allow processing of antigen-loaded microparticles leading to MHC presentations to 
the immune cells.  
 
3.3. Immunization suppresses tumor growth 
At the end of vaccination, 107 ID8 cells were injected subcutaneously to the animals of each 
study group and the tumor volumes were measured every week using digital Vernier calipers. In 
the control group, mice were treated with placebo particles and the tumor developed rapidly. 
However, vaccinated mice showed tumor suppression when compared to the control/ placebo 
group as shown in figure 2.  
Vaccine alone resulted in around 1.5 times tumor suppression in case of transdermal and 
combination of routes at the end of 15th week. In case of interleukins, transdermal route showed 
around 3 times of tumor suppression and combination of routes resulted in around 9 times of 
tumor suppression, when compared to control mice. Transdermally vaccinated mice showed 
significant retardation of tumor volume in comparison to control animals at 12th week after the 
tumor challenge (p<0.05), while mice vaccinated with combination of two routes showed 
significant retardation at 15th week after tumor challenge. The tumor volume measurements 
obtained are shown in figure 2.  
Fig.2 Immunization with vaccine microparticles suppresses tumor growth: Mean tumor volumes 
for mice groups treated with two different approaches: (A) Transdermal (B) Transdermal + Oral 
vaccination: Placebo, vaccine microparticles with and without interleukins. The tumor volume 
was monitored with the aid of Vernier calipers on a weekly basis. Vaccinated mice showed 
higher tumor suppression as compared to non-vaccinated/placebo treated mice for (A) 
Transdermal (B) Transdermal + Oral vaccination groups  (p<0.05), *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
 
In case of transdermal route, there was no significant difference between vaccine and vaccine 
with interleukin groups in terms of tumor volumes. This can be due to the interleukin 
concentration used in vaccine which was not high enough to retard tumor growth more than that 
seen with vaccine alone. Higher concentration of interleukins might be needed to show 
additional tumor suppression. However, in case of combination routes, a significant difference 
was seen in tumor volumes of vaccine with and without interleukins at 12th week (p<0.05) and 
15th week (p<0.0001). The interleukins were found to contribute to even more tumor suppression 
when administered via oral as well as transdermal route.  
 
3.4. Immunization with vaccine microparticles generates humoral immune response and 
interleukins influence Th1/Th2 response 
In order to determine B-cell response, the serum samples collected in between doses were 
analyzed by ELISA. Immunized mice showed elevated IgG titers as compared to control ones at 
the end of transdermal vaccination (p<0.01) as shown in figure 3(A). For combination route 
(figure 3(B)), mice vaccinated with interleukins showed elevated response as compared to 
control mice (p < 0.01) and mice treated with vaccine particles alone (p < 0.05) at the end of 
second dosing.  At the end of vaccination, it resulted in elevated titers in vaccinated mice as 
compared to control mice and incorporation of interleukins resulted in further increase in titers. 
(A) (B) 
Fig. 3: Humoral response obtained with Immunization with vaccine microparticles for mice 
groups treated with two different approaches: (A) Transdermal (B) Transdermal + Oral 
vaccination: Placebo, vaccine microparticles with and without interleukins. Serum IgG titers 
determined by ELISA, showing higher titers at the end of final vaccination in case of mice in (A) 
Transdermal (B) Transdermal + Oral vaccination groups with and without interleukins when 
compared to mice treated with placebo microparticles, while only in case of combination routes, 
the IgG titers were elevated even further upon addition of interleukins. (p<0.05), *p<0.05, 
**p<0.01, ****p<0.0001  
 
Serum IgG1 titers (indicative of Th2 response) and IgG2a titers (indicative of Th1 response) 
were elevated in mice vaccinated with interleukins when compared to control mice in case of 
both study approaches as shown in figure 4 (A, B) and 5(A, B) respectively. Thus, both subtypes 
Type to 
  (A) 
         
(B) 
of IgGs indicate that mixed Th1 and Th2 immune response was generated in case of vaccine with 
interleukins group. 
Fig. 4: IgG1 humoral immune response (indicative of Th2 response) for mice groups treated with 
two different approaches: (A) Transdermal (B) Transdermal + Oral vaccination: Placebo, vaccine 
microparticles with and without interleukins. Serum IgG1 titers determined by ELISA, showing 
higher titers in case of mice vaccinated with interleukins as compared to placebo treated/ non-
vaccinated mice. Vaccine with interleukins showed even further elevation in IgG1 titers in case 
of combination route of vaccination. (p<0.05), *p<0.05, **p<0.01, ***p<0.001 
Fig.5. IgG2a humoral immune response (indicative of Th1 response) for mice groups treated 
with two different approaches: (A) Transdermal (B) Transdermal + Oral vaccination: Placebo, 
vaccine microparticles with and without interleukins. Serum IgG2a titers determined by ELISA, 
showing higher titers in case of mice vaccinated with interleukins as compared to placebo 
treated/ non-vaccinated mice. (p<0.05), *p<0.05 
 
Stimulation of immune system as a function of a vaccine is mainly based on humoral and cellular 
response reflected in serum and lymphatic organs of the body. Humoral response is majorly read 
as IgG antibodies secreted by B-cell activation. Moreover, IgG subtypes such as IgG1 and IgG2a 
were determined in serum samples which are indicative of Th2 and Th1 response respectively. 
The Th1 response indicates that T-helper cells (CD4+ T-cells) are activated to trigger 
macrophages and cytotoxic (CD8+) T-cells, hence further cascade of immune pathway. On the 
other hand, Th2 response depicts that CD4+ T-cells are triggered to activate B- cells (humoral 
arm of immune response).  
Serum IgG levels were found to be elevated at the end of dosing in case of vaccinated mice via 
both study approaches and interleukins showed further rise in levels of IgG only in case of 
combination routes. Thus, humoral response was triggered by these particulate vaccines upon 
oral and transdermal administration. Further, there was an elevation in IgG1 and IgG2a titers in 
mice vaccinated with interleukins in case of both study approaches. This indicates the activation 
of Th1 and Th2 response only in presence of interleukins administered via transdermal and 
combination route. Vaccine treated mice did not show any elevation in titers which again 
indicated the influence of interleukins mediating Th1 and Th2 pathway. Thus vaccine with 
interleukins resulted in mixed response of Th1 and Th2 pathways. This humoral response 
complied with tumor challenge study results where interleukins group showed further 
suppression of tumor for combination routes of vaccination. Only combination route showed 
increase in IgG1 and IgG2a titers along with elevated IgG titers upon vaccination with 
interleukins when compared to control and mice treated with vaccine particles alone. This 
complied with the findings on tumor suppression. 
 
3.5. Immunization generates T-cell based/ cellular immune response  
The second array of cancer immune response comprises of activation of T-cytotoxic (CD8+) and 
T-helper (CD4+), Natural Killer (NK) cells which contribute to cellular response. For this 
purpose, splenocytes were screened for specific cell markers by flow cytometry to determine 
CD8+, CD4+ T-cell and NK-cell populations and the results obtained are shown in figure 6. 
 
In case of transdermal immunization, CD8+ T-cell populations were found to be elevated in all 
vaccinated mice when compared to control group as shown in figure 6 (A). Moreover, the 
inclusion of interleukins in the vaccine resulted in further elevation in this cytotoxic T-cell 
population (p<0.05). In case of immunization via combination of two routes, vaccine alone did 
not result in any significant increase in this cell count as shown in figure 6 (B). However, 
vaccine with interleukins resulted in higher population than vaccine alone as well as control 
group. This difference in CD8+ T-cells response in terms of route can be attributed to the dosing 
regimen followed for transdermal (10 doses of vaccine via skin) and combination route (5 doses 
of vaccine via skin and 5 doses via oral route). 
 
In case of CD4+ T-cell titers, all vaccinated groups showed significant rise in level of these cells 
as shown in figure 6 (C, D). However, further elevation in CD4+ T-cell population was not seen 
upon inclusion of interleukins (p<0.05). 
We also analyzed NK-cell populations in splenocytes. We found that all vaccinated mice 
demonstrated higher levels of NK-cells when compared to control mice. On the other hand, in 
case of transdermal vaccination, interleukins group showed lower NK-cell titers than the one 
obtained in vaccine alone group. However, the incorporation of interleukins resulted in even 
further elevation in case of combination routes other than transdermal vaccination as shown in 
figure 6 (E and F) (p<0.05). Transdermally vaccinated mice received vaccine particles via skin 
for 10 times; while combination route delivered 5 doses via skin and 5 oral doses administered 
alternatively. This NK-cell activity seen in combination appeared to play a major role in tumor 
suppression based upon overall analysis of immune response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. T-cell based/ cellular immune response: CD8+ T-cells population determined by flow 
cytometry for mice treated with (A) Transdermal (B) Transdermal + Oral vaccination; CD4+ T-
cells population determined by flow cytometry for mice treated with (C) Transdermal (D) 
Transdermal + Oral vaccination and NK-cells population determined by flow cytometry for mice 
treated with (E) Transdermal (F) Transdermal + Oral vaccination. *p<0.05, **p<0.01, 
***p<0.001  
 
The overall results obtained are summarized in table 1 to provide a statistical comparison 
between the two routes of vaccine delivery. The symbol ‘*’ is used to indicate the statistically 
significant difference compared to control/ placebo mice (PL); while this difference is 
represented with letter ‘a’ for comparison between vaccine  (V) and vaccine with interleukins 
group (V + IL). When data was analyzed for vaccinated and control/placebo mice, tumor 
suppression was seen in case of both transdermal and combination routes as indicated by ‘*’. 
Interleukins were found to result in further suppression only in case of combination routes as 
indicated by ‘a’. Further the level of significance for each comparison is described in the table 1 
caption. In case of interleukins, transdermal route showed around 3 times of tumor suppression 
and combination of routes resulted in around 9 times of tumor suppression, when compared to 
control mice. Thus, the combination route was found to the more effective route for suppression 
of tumor when vaccine was administered along with interleukins. In order to understand the 
mechanism behind this effect, we performed analysis of humoral as well as cellular response. As 
indicated in Table 1, for combination route, the vaccine with interleukins group showed elevated 
response in almost all humoral and cellular responses as represented by level of significance with 
letter ‘a’ when compared to vaccine alone group. This effect (indicated by letter ‘a’ in table 1) 
was not seen in case of transdermal vaccination to the extent seen in combination route. This 
correlated with the tumor retardation response seen in case of combination route when 
vaccinated with interleukins. Thus, the study concludes that the combination route of vaccine 
delivery in presence of interleukins provides an improved humoral/cellular immune response that 
is capable of providing protection against tumor growth, as seen with this murine model for 
ovarian cancer.  
 
The overall stimulation of humoral and cellular response upon vaccination indicates the efficacy 
of the vaccine microparticles.  Moreover, the immune stimulation in terms of humoral and 
cellular response obtained correlated with tumor volume retardation. This study indicated that 
humoral response as well as cellular response was needed for tumor suppression. This finding 
correlated with the study reported by Mahmoud SM et al., where it was found that the humoral 
immunity is important in addition to cell-mediated immunity in prognosis of breast cancer [26]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Summary of results obtained from in-vivo study of ovarian cancer vaccine 
microparticles via two different study approaches based on route of administration 
1at the end of 15th week, PL=Placebo, V= Vaccine, V + ILs= Vaccine with interleukins, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, results expressed in comparison to mice treated 
with placebo particles within each study approach based on route of administration 
ap<0.05, aap<0.01, aaap<0.001, aaaap<0.0001 results expressed for comparison between vaccine 
and vaccine with interleukins groups within each study approach based on route of 
administration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Conclusion 
The efficacy of vaccine microparticles containing whole cell lysate of ID8 ovarian cancer cells in 
retarding tumor growth in murine models was demonstrated in this study via two different study 
approaches based on routes of administration. Thus, the microparticulate vaccine when given via 
combination of oral and transdermal routes provides a promising approach in terms of cost-
effectiveness, ease of production and patient compatibility. Vaccine with interleukins when 
administered via combination of two routes was found to result in higher tumor suppression in 
correlation to cellular and humoral response as compared to other routes. This study was 
performed in prophylactic setting to check the efficacy of particles, which forms the strong basis 
for further studies to evaluate therapeutic efficacy of the particles in tumor bearing animals. 
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